TY - JOUR
T1 - Correction to
T2 - SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion (Trials, (2021), 22, 1, (550), 10.1186/s13063-021-05461-9)
AU - and the CDD SPIKE-1 Project Team
AU - Halford, Sarah
AU - Wan, Susan
AU - Dragoni, Ilaria
AU - Silvester, Julie
AU - Nazarov, Bobojon
AU - Anthony, Daniel
AU - Anthony, Suzie
AU - Ladds, Emma
AU - Norrie, John
AU - Dhaliwal, Kevin
PY - 2022/4/21
Y1 - 2022/4/21
N2 - Following the publication of the original article [1], we were notified that the Flu-iiQ™ table included in the supplementary material of original publication needs to be deleted. The authors were not at liberty to publish the table in full as a number of the items listed are confidential and commercially sensitive. For full details of the Flu-iiQ™ questionnaire please contact Measured Solutions P/L, PO Box 5127, Alphington VIC 3079, Australia (measuredsolutions.com.au). The original article has been corrected.
AB - Following the publication of the original article [1], we were notified that the Flu-iiQ™ table included in the supplementary material of original publication needs to be deleted. The authors were not at liberty to publish the table in full as a number of the items listed are confidential and commercially sensitive. For full details of the Flu-iiQ™ questionnaire please contact Measured Solutions P/L, PO Box 5127, Alphington VIC 3079, Australia (measuredsolutions.com.au). The original article has been corrected.
UR - http://www.scopus.com/inward/record.url?scp=85128591192&partnerID=8YFLogxK
U2 - 10.1186/s13063-022-06266-0
DO - 10.1186/s13063-022-06266-0
M3 - Comment/debate
C2 - 35449061
AN - SCOPUS:85128591192
SN - 1745-6215
VL - 23
JO - Trials
JF - Trials
IS - 1
M1 - 336
ER -